Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Otago researchers receive new joint research funding


Thursday 2 March 2017

Otago researchers receive new joint pharmaceuticals research funding

Researchers from University of Otago are among the first recipients of two new grants from PHARMAC and the Health Research Council of New Zealand (HRC).

Dr Lianne Parkin of the Department of Preventive and Social Medicine receives a grant worth more than $210,000 for research into metformin use by people with diabetes. This drug is the first-line treatment for type 2 diabetes, however overseas research shows that many patients do not use it as prescribed.

Dr Parkin and colleagues will explore how to improve the way New Zealanders with type 2 diabetes use metformin.

PHARMAC Chief Executive Steffan Crausaz and HRC Chief Executive Professor Kath McPherson announced the first recipients of the joint fund today.

Mr Crausaz says the two studies will provide valuable insights into how New Zealanders can get the best out of medicines.

“Our objective in setting up the fund with the HRC was to improve our knowledge of medicines use in New Zealand, so that we can take steps to improve people’s use of medicines,” he says.

“Metformin is an important medicine for people with type 2 diabetes, so Dr Parkin’s research will give us a better idea as to why people might not continue taking the medicine they need to keep them well.”

Dr McPherson says the collaboration with PHARMAC is providing a further opportunity to grow innovative research into pharmaceuticals in New Zealand.

“We’re delighted to be involved in this research initiative with PHARMAC. This is a great example of government health organisations collaborating to benefit patients and strengthen the use of research evidence to improve our health system overall.

“I’m confident that the studies funded through this partnership initiative will be of a high quality and add to our knowledge of how New Zealanders use medicines.”

Project details:

Improving metformin adherence and persistence in people with type 2 diabetes
$213,229, 24 months

Principal Investigator: Dr Lianne Parkin. The other investigators are Dr Simon Horsburgh (Preventive and Social Medicine), Mr Dave Barson (Preventive and Social Medicine), Associate Professor Katrina Sharples (Mathematics and Statistics, and Medicine), Dr Jimmy Zeng (Preventive and Social Medicine), Dr Lisa Te Morenga (Associate Dean (Māori), Division of Sciences; Edgar Diabetes and Obesity Research Centre; Human Nutrition), Faumuina Associate Professor Fa’afetai Sopoaga (Associate Dean (Pacific), Division of Health Sciences; Preventive and Social Medicine). Five of the researchers are core members of the Pharmacoepidemiology Research Network at the University.

Type 2 diabetes imposes a substantial burden on New Zealanders, particularly Māori and Pacific peoples. Metformin is the first-line medication for the treatment of type 2 diabetes, but overseas research has found that many patients have suboptimal metformin adherence and persistence. Persistence refers to whether a person stays on a therapy, while adherence refers to whether a person takes a medication according to the prescribed schedule. Suboptimal metformin adherence and persistence are important because they are associated with a higher risk of diabetes complications.

The researchers will use routinely collected health data to (a) describe the patterns of metformin adherence and persistence in New Zealanders with type 2 diabetes, and (b) investigate the predictors and consequences of suboptimal adherence and persistence. They will also interview people with type 2 diabetes to get their views on what helps, and hinders, good metformin adherence and persistence. The findings will contribute to improved outcomes for people prescribed metformin.

ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

NZ's Space Programme: Rocket Lab Makes It To Space (But Not Orbit)

Electron lifted-off at 16:20 NZST from Rocket Lab Launch Complex 1 on the Mahia Peninsula in New Zealand. It was the first orbital-class rocket launched from from a private launch site in the world. More>>

ALSO:

Earlier:

Budget: Irrigate (Good Times, Come On!)

Additional grant funding of $26.7 million over the next three years plus a capital boost of $63 million towards irrigation investments in Budget 2017 will deliver economic and environmental benefits through better use of water... More>>

ALSO:

Silver Fern Farms: Proposal To Close Fairton Sheepmeat Plant

Silver Fern Farms has advised its people of the proposal to permanently close the site, and has discussed potential transfer options to its other sites in the region as part of the consultation process...
More>>

ALSO:

MPI: Myrtle Rust Appears In Taranaki

The nursery in Waitara (just north of New Plymouth) reported suspected myrtle rust symptoms on young plants to the Ministry’s 0800 number yesterday (Tuesday). More>>

ALSO: